Cannovex is a biotech company developing cannabinoid-based medicines to improve the lives of patients around the world.

Over a period of two years, Cannovex conducted an in-depth study of the medical literature on this subject.

These difficult aspects make Cannovex the preferred discussion partner, sounding board and source of information about cannabinoid medicines for everyone involved.

Based on the significance derived from the sustained research, Cannovex now plans the development of cannabinoid-based medicines in specific therapeutic areas (e.g. pain management) and for good indications. Cannovex aims to set up clinical studies, in collaboration with university hospitals in the EU, to provide proofs of concept (PoC). Based on these PoCs, Cannovex will explore partnerships with pharmaceutical companies to conduct end-stage clinical trials, apply for market authorization with the European Medicines Agency (EMA) and potential agents, and commercialize our cannabinoid medicines globally.